Patent ID: 8952012
Filing Date: 2015-02-10
Classification: A01K,A61K,C12N,C12Q,C12Y,G01N

Abstract:
1. A method for identifying a test compound as a candidate compound for the treatment of a cardiometabolic disease or disorder in a mammal by inhibition of delta-6 desaturase, the method comprising a) contacting a mammalian delta-6 desaturase (D6D) with the test compound; b) determining a change in the level of at least one index of D6D activity in the presence of the test compound, wherein the at least one index of D6D activity is selected from the arachidonic acid/linoleic acid (AA/LA) ratio, or the level of a proinflammatory eicosanoid; and c) determining a change in the level of at least one index of a cardiometabolic disease-related disorder, wherein the at least one index of the cardiometabolic disease-related disorder is selected from any one or more of: blood or serum glucose level, glucose tolerance, blood or serum insulin level, insulin resistance, liver macrophage content, or insulin receptor inactivation (IRS-1 phosphorylation); wherein a decreased level of D6D activity and a decreased level of a cardiometabolic disease-related disorder in the presence of the test compound relative to a level of D6D activity and a level of a cardiometabolic disease-related disorder in the absence of the test compound identifies the test compound as a candidate compound for the treatment of a cardiometabolic disease or disorder in a mammal.